The weekly litigation news digest is live. Subscribe now
Treatment Of Cancer - EP4096717
The patent EP4096717 was granted to Innate Pharma on Dec 11, 2024. The application was originally filed on Jan 28, 2021 under application number EP21702624A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP4096717
- Application Number
- EP21702624A
- Filing Date
- Jan 28, 2021
- Status
- Granted And Under Opposition
- Nov 8, 2024
- Publication Date
- Dec 11, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Antibody-drug conjugates (ADCs) targeting Nectin-4 for treating cancers with low or heterogeneous Nectin-4 expression, including bladder, breast, lung, and pancreatic cancers. The ADCs comprise a Nectin-4-binding antibody conjugated to a camptothecin analogue, such as exatecan, through a cleavable linker. The ADCs can be used in patients with Nectin-4-expressing cancers who have received prior chemotherapy or have resistance to HER2-targeted therapies. The ADCs exhibit improved efficacy and reduced toxicity compared to existing Nectin-4-targeted ADCs, enabling treatment of patients with low or moderate Nectin-4 expression levels.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (31) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents